Prevalence of COPD in Our Lung Cancer Population, Compared to Controls
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02603627|
Recruitment Status : Unknown
Verified October 2015 by Guy's and St Thomas' NHS Foundation Trust.
Recruitment status was: Not yet recruiting
First Posted : November 13, 2015
Last Update Posted : November 13, 2015
|Condition or disease|
|COPD Lung Cancer Smoking|
Chronic obstructive pulmonary disease (COPD) is a breathing problem that some people develop. Usually it is caused by smoking. Damage to the lungs means that patients are at risk of more chest infections and are unable to exercise like healthy individuals. They may also have a long-standing cough.
COPD is diagnosed by testing lung function, usually using a small device called a spirometer.
COPD is becoming a better understood condition. It is known that the lungs of patients with COPD are sometimes inflamed. This is important because inflammation is associated with some types of cancer, including lung cancer.
The investigators are interested in whether COPD puts people at higher risk of lung cancer. They would like to find out how common COPD is in patients who have lung cancer. The investigators would also like to find out how common COPD is in patients who are not known to have lung cancer (comparison group). This will help them interpret their results better as investigators will be able to compare the two groups.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Cross-sectional Study to Compare the Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in Patients Newly Diagnosed With Lung Cancer, Compared to Controls|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||August 2016|
With lung cancer
Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
Without lung cancer
Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
- Prevalence of COPD in lung cancer compared to controls, using spirometry to diagnose COPD. [ Time Frame: Up to nine months ]
- Comparison of the proportion of small cell tumours to non-small cell tumours in patients with lung cancer and COPD. [ Time Frame: Up to nine months ]No change to routine care (no extra specimens to be taken or retained), but data on the histological subtypes will be recorded (as described above) to better inform the investigators about whether COPD-associated lung cancer demonstrates a different histological subtype.
- Comparison of the proportion of individuals with an emphysematous phenotype to the proportion of individuals with a bronchitic phenotype. [ Time Frame: Up to nine months ]No change to routine care (no extra investigations to be performed), but data on the radiological phenotype will be recorded to better inform the investigators about whether patients with COPD-associated lung cancer tend to have an emphysematous COPD pattern or a bronchitic one.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02603627
|Contact: Alex Cumberworth, BM BS BScemail@example.com|
|Guy's and St Thomas' NHS Foundation Trust|
|London, England, United Kingdom, SE1 9RT|
|Contact: Tariq Sethi, MBBS PhD 02032993165|
|Principal Investigator: Anthony Dorr, MBBS PhD|
|Principal Investigator: Tariq Sethi, MBBS PhD|
|Principal Investigator:||Tariq Sethi, MBBS PhD||King's Health Partners|
|Principal Investigator:||Anthony Dorr, MBBS PhD||Guy's and St Thomas' NHS Foundation Trust|